Jazz Pharmaceuticals Analyst Ratings
Jazz Pharmaceuticals (JAZZ) Receives a Hold From Morgan Stanley
RBC Trims Price Target on Jazz Pharmaceuticals to $175 From $176, Keeps Outperform Rating
Jazz Pharmaceuticals Analyst Ratings
Jazz Pharmaceuticals Analyst Ratings
Jazz Pharmaceuticals Analyst Ratings
UBS Adjusts Price Target on Jazz Pharmaceuticals to $117 From $121, Maintains Neutral Rating
Jazz Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Jazz Pharmaceuticals (JAZZ) and KalVista Pharmaceuticals (KALV)
RBC Capital Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Jazz Pharmaceuticals Analyst Ratings
Buy Rating Affirmed: Jazz Pharmaceuticals' Resilient Base and Promising Pipeline Drive Positive Outlook
Barclays Remains a Buy on Jazz Pharmaceuticals (JAZZ)
Jazz Pharmaceuticals (JAZZ) Gets a Buy From Barclays
Jazz Pharmaceuticals Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT) and Jazz Pharmaceuticals (JAZZ)
JPMorgan Raises Jazz Pharmaceuticals' Price Target to $190 From $170, Maintains Overweight Rating
Jazz Pharmaceuticals Analyst Ratings
Optimistic Outlook on Jazz Pharmaceuticals' Zanidatamab Across Multiple Cancer Types: A Buy Rating Analysis
Buy Rating Affirmed for Jazz Pharmaceuticals on Strong Zanidatamab Revenue Prospects and Clinical Milestones